Contingent Value Right (CVR) Illiquidity
The Formal Definition
A post-merger contractual derivative security granted to target shareholders that pays a variable cash or stock dividend only if specific milestone events (such as FDA approvals or revenue targets) are achieved, typically trading at severe illiquidity discounts on over-the-counter markets.
CVR Fair Value = ∑ [ P(Milestone Achievement_i) × Discounted Target Payout_i ] - Illiquidity Haircut %
Cole Barrett's Reality Check
The Unvarnished Bottom Line"CVRs are the corporate finance equivalent of an un-scratched lottery ticket. In biotech takeovers, the buyer offers $20 in cash plus a 'Contingent Value Right' promising an extra $5 if an experimental drug gets FDA approval by 2027. Most institutional funds can't hold unlisted paper, so they dump their CVRs on pink sheets for 40 cents on the dollar, leaving retail holders stuck in an illiquid, opaque asset."
Interactive Simulator: Test the Math
Real-World Example: Scenario Breakdown
Examining the real numbers for: Holding 5,000 Contingent Value Rights issued following the acquisition of a clinical-stage biotechnology company
| Execution Metric | Special Situations Arbitrageur | Unprepared Retail Target Shareholder |
|---|---|---|
| Fee / Rate | $10 OTC ticket fee | $0 account fees |
| Spread / Buffer | Analyzed FDA trial clinical data; bought dumped institutional CVRs at an 85% discount for $0.45 each | Received 5,000 CVRs automatically after the merger; broker charged a $25 annual custody fee on unlisted securities |
| Execution / Status | Drug received surprise FDA approval 18 months later; acquirer was contractually obligated to pay the full $4.00 cash milestone | Tried to sell the CVRs during a personal emergency: the OTC bid-ask spread was a massive $0.20 Bid / $0.60 Ask |
| Total Cost / Result | Monetized structural illiquidity and milestone realization | Suffered severe losses from OTC illiquidity and wide bid-ask spreads |
How Brokers Weaponize This Term
If you receive CVRs from a corporate takeover, check whether your broker charges monthly or annual 'Custody Fees for Unlisted/Restricted Assets'. Certain legacy brokers assess $50 to $100 per year just to maintain unlisted CVR positions on your ledger.
Broker Evaluation Matrix
Cole Approves
Interactive Brokers: Supports over-the-counter (OTC) trading and custodial tracking of corporate actions, rights, and CVR instruments with transparent fee schedules.
Read Audit →Cole Flags / Avoids
Mobile Neobrokers: Often forces the automatic cash liquidation of unlisted CVRs at whatever bid the dealer quotes, because their apps cannot support OTC securities.
View Trap Details →Frequently Asked Questions
Can Contingent Value Rights expire worthless?
Yes. If the underlying corporate milestone (e.g., FDA drug approval or revenue hurdle) is not achieved before the contractual expiration date, the CVR expires completely worthless with $0 value.
Do all CVRs trade on public exchanges?
No. Many CVRs are non-transferable, meaning you cannot sell them on any exchange; you must hold them until either the milestone is paid or the contract expires.